Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Cancer Drug Resist ; 6(4): 748-767, 2023.
Article in English | MEDLINE | ID: mdl-38263981

ABSTRACT

Tumors survive by creating a tumor microenvironment (TME) that suppresses antitumor immunity. The TME suppresses the immune system by limiting antigen presentation, inhibiting lymphocyte and natural killer (NK) cell activation, and facilitating T cell exhaustion. Checkpoint inhibitors like anti-PD-1 and anti-CTLA4 are immunostimulatory antibodies, and their blockade extends the survival of some but not all cancer patients. Extracellular adenosine triphosphate (ATP) is abundant in inflamed tumors, and its metabolite, adenosine (ADO), is a driver of immunosuppression mediated by adenosine A2A receptors (A2AR) and adenosine A2B receptors (A2BR) found on tumor-associated lymphoid and myeloid cells. This review will focus on adenosine as a key checkpoint inhibitor-like immunosuppressive player in the TME and how reducing adenosine production or blocking A2AR and A2BR enhances antitumor immunity.

2.
Cells ; 10(9)2021 08 27.
Article in English | MEDLINE | ID: mdl-34571866

ABSTRACT

Cancer-specific plectin (CSP) is a pro-tumorigenic protein selectively expressed on the cell surface of major cancers, including ovarian cancer (OC). Despite its assessable localization, abundance, and functional significance, the therapeutic efficacy of targeting CSP remains unexplored. Here, we generated and investigated the anticancer effects of a novel CSP-targeting monoclonal antibody, 1H11, in OC models. Its therapeutic efficacy as a monotherapy and in combination with chemotherapy was evaluated in vitro using two OC cell lines and in vivo by a subcutaneous ovarian cancer model. 1H11 demonstrated rapid internalization and high affinity and specificity for both human and murine CSP. Moreover, 1H11 induced significant and selective cytotoxicity (EC50 = 260 nM), G0/G1 arrest, and decreased OC cell migration. Mechanistically, these results are associated with increased ROS levels and reduced activation of the JAK2-STAT3 pathway. In vivo, 1H11 decreased Ki67 expression, induced 65% tumor growth inhibition, and resulted in 30% tumor necrosis. Moreover, 1H11 increased chemosensitivity to cisplatin resulting in 60% greater tumor growth inhibition compared to cisplatin alone. Taken together, CSP-targeting with 1H11 exhibits potent anticancer activity against ovarian cancer and is deserving of future clinical development.


Subject(s)
Antibodies, Monoclonal/pharmacology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Ovarian Neoplasms/drug therapy , Plectin/pharmacology , Animals , Carcinoma, Ovarian Epithelial/drug therapy , Carcinoma, Ovarian Epithelial/metabolism , Cell Line, Tumor , Cisplatin/pharmacology , Drug Resistance, Neoplasm/drug effects , Female , Humans , Janus Kinase 2/metabolism , Mice , Ovarian Neoplasms/metabolism , Phosphorylation/drug effects , STAT3 Transcription Factor/metabolism , Signal Transduction/drug effects , Xenograft Model Antitumor Assays/methods
3.
Am J Physiol Lung Cell Mol Physiol ; 318(2): L304-L313, 2020 02 01.
Article in English | MEDLINE | ID: mdl-31800262

ABSTRACT

Primary graft dysfunction after lung transplantation, a consequence of ischemia-reperfusion injury (IRI), is a major cause of morbidity and mortality. IRI involves acute inflammation and innate immune cell activation, leading to rapid infiltration of neutrophils. Formyl peptide receptor 1 (FPR1) expressed by phagocytic leukocytes plays an important role in neutrophil function. The cell surface expression of FPR1 is rapidly and robustly upregulated on neutrophils in response to inflammatory stimuli. Thus, we hypothesized that use of [99mTc]cFLFLF, a selective FPR1 peptide ligand, would permit in vivo neutrophil labeling and noninvasive imaging of IRI using single-photon emission computed tomography (SPECT). A murine model of left lung IRI was utilized. Lung function, neutrophil infiltration, and SPECT imaging were assessed after 1 h of ischemia and 2, 12, or 24 h of reperfusion. [99mTc]cFLFLF was injected 2 h before SPECT. Signal intensity by SPECT and total probe uptake by gamma counts were 3.9- and 2.3-fold higher, respectively, in left lungs after ischemia and 2 h of reperfusion versus sham. These values significantly decreased with longer reperfusion times, correlating with resolution of IRI as shown by improved lung function and decreased neutrophil infiltration. SPECT results were confirmed using Cy7-cFLFLF-based fluorescence imaging of lungs. Immunofluorescence microscopy confirmed cFLFLF binding primarily to activated neutrophils. These results demonstrate that [99mTc]cFLFLF SPECT enables noninvasive detection of lung IRI and permits monitoring of resolution of injury over time. Clinical application of [99mTc]cFLFLF SPECT may permit diagnosis of lung IRI for timely intervention to improve outcomes after transplantation.


Subject(s)
Lung/diagnostic imaging , Lung/pathology , Oligopeptides/chemistry , Receptors, Formyl Peptide/metabolism , Reperfusion Injury/diagnostic imaging , Tomography, Emission-Computed, Single-Photon , Animals , Lung/physiopathology , Mice, Inbred C57BL , Neutrophil Infiltration , Optical Imaging , Tissue Distribution
4.
Clin Transl Med ; 8(1): 12, 2019 Apr 15.
Article in English | MEDLINE | ID: mdl-30989390

ABSTRACT

Chronic obstructive pulmonary disease (COPD) is expected to climb on the podium of the leading causes of mortality worldwide in the upcoming decade. Clinical diagnosis of COPD has classically relied upon detecting irreversible airflow obstruction on pulmonary function testing as a global assessment of pulmonary physiology. However, the outcome is still not favorable to decrease mortality due to COPD. Progress made in both medical and molecular imaging fields are beginning to offer additional tools to address this clinical problem. This review aims to describe medical and molecular imaging modalities used to diagnose COPD and to select patients for appropriate treatments and to monitor response to therapy.

5.
Respir Res ; 19(1): 17, 2018 01 24.
Article in English | MEDLINE | ID: mdl-29368614

ABSTRACT

Imaging holds an important role in the diagnosis of lung diseases. Along with clinical tests, noninvasive imaging techniques provide complementary and valuable information that enables a complete differential diagnosis. Various novel molecular imaging tools are currently under investigation aimed toward achieving a better understanding of lung disease physiopathology as well as early detection and accurate diagnosis leading to targeted treatment. Recent research on molecular imaging methods that may permit differentiation of the cellular and molecular components of pulmonary disease and monitoring of immune activation are detailed in this review. The application of molecular imaging to lung disease is currently in its early stage, especially compared to other organs or tissues, but future studies will undoubtedly reveal useful pulmonary imaging probes and imaging modalities.


Subject(s)
Lung Diseases/diagnostic imaging , Lung Diseases/metabolism , Molecular Imaging/methods , Diagnosis, Differential , Graft Rejection/diagnostic imaging , Graft Rejection/metabolism , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/metabolism , Molecular Imaging/trends
6.
Circ Res ; 120(10): 1598-1613, 2017 May 12.
Article in English | MEDLINE | ID: mdl-28232595

ABSTRACT

RATIONALE: Virtually all mesenchymal stem cell (MSC) studies assume that therapeutic effects accrue from local myocardial effects of engrafted MSCs. Because few intravenously administered MSCs engraft in the myocardium, studies have mainly utilized direct myocardial delivery. We adopted a different paradigm. OBJECTIVE: To test whether intravenously administered MSCs reduce left ventricular (LV) dysfunction both post-acute myocardial infarction and in ischemic cardiomyopathy and that these effects are caused, at least partly, by systemic anti-inflammatory activities. METHODS AND RESULTS: Mice underwent 45 minutes of left anterior descending artery occlusion. Human MSCs, grown chronically at 5% O2, were administered intravenously. LV function was assessed by serial echocardiography, 2,3,5-triphenyltetrazolium chloride staining determined infarct size, and fluorescence-activated cell sorting assessed cell composition. Fluorescent and radiolabeled MSCs (1×106) were injected 24 hours post-myocardial infarction and homed to regions of myocardial injury; however, the myocardium contained only a small proportion of total MSCs. Mice received 2×106 MSCs or saline intravenously 24 hours post-myocardial infarction (n=16 per group). At day 21, we harvested blood and spleens for fluorescence-activated cell sorting and hearts for 2,3,5-triphenyltetrazolium chloride staining. Adverse LV remodeling and deteriorating LV ejection fraction occurred in control mice with large infarcts (≥25% LV). Intravenous MSCs eliminated the progressive deterioration in LV end-diastolic volume and LV end-systolic volume. MSCs significantly decreased natural killer cells in the heart and spleen and neutrophils in the heart. Specific natural killer cell depletion 24 hours pre-acute myocardial infarction significantly improved infarct size, LV ejection fraction, and adverse LV remodeling, changes associated with decreased neutrophils in the heart. In an ischemic cardiomyopathy model, mice 4 weeks post-myocardial infarction were randomized to tail-vein injection of 2×106 MSCs, with injection repeated at week 3 (n=16) versus PBS control (n=16). MSCs significantly increased LV ejection fraction and decreased LV end-systolic volume. CONCLUSIONS: Intravenously administered MSCs for acute myocardial infarction attenuate the progressive deterioration in LV function and adverse remodeling in mice with large infarcts, and in ischemic cardiomyopathy, they improve LV function, effects apparently modulated in part by systemic anti-inflammatory activities.


Subject(s)
Cardiomyopathies/therapy , Mesenchymal Stem Cell Transplantation/methods , Myocardial Infarction/therapy , Myocardial Ischemia/therapy , Ventricular Dysfunction, Left/therapy , Administration, Intravenous , Animals , Cardiomyopathies/immunology , Cardiomyopathies/physiopathology , Cells, Cultured , Humans , Male , Mesenchymal Stem Cells/immunology , Mice , Myocardial Infarction/immunology , Myocardial Infarction/physiopathology , Myocardial Ischemia/immunology , Myocardial Ischemia/physiopathology , Treatment Outcome , Ventricular Dysfunction, Left/immunology , Ventricular Dysfunction, Left/physiopathology
7.
Nat Rev Gastroenterol Hepatol ; 14(2): 97-109, 2017 02.
Article in English | MEDLINE | ID: mdl-27826137

ABSTRACT

Pancreatic diseases, chronic pancreatitis, pancreatic cancer and diabetes mellitus, taken together, occur in >10% of the world population. Pancreatic diseases, as with other diseases, benefit from early intervention and appropriate diagnosis. Although imaging technologies have given clinicians an unprecedented toolbox to aid in clinical decision-making, advances in these technologies and development of molecular-based diagnostic tools could enable physicians to identify diseases at an even earlier stage and, thereby, improve patient outcomes. In this Review, we discuss and identify gaps in the use of imaging techniques for the early detection and appropriate treatment stratification of various pancreatic diseases, including diabetes mellitus, acute and chronic pancreatitis and pancreatic cancer. Imaging techniques discussed are MRI, CT, PET and ultrasonography. Additionally, the identification of new molecular targets for imaging and the development of contrast agents that are able to give molecular information in noninvasive radionuclear imaging and ultrasonography are emerging areas of innovation that could lead to increased diagnostic accuracy and improved patient outcomes.


Subject(s)
Pancreatic Diseases/diagnostic imaging , Biomarkers/metabolism , Clinical Decision-Making , Early Diagnosis , Humans , Magnetic Resonance Imaging , Pancreatic Diseases/metabolism , Pancreatic Diseases/therapy , Positron-Emission Tomography , Tomography, X-Ray Computed , Ultrasonography
8.
Cancer J ; 21(3): 188-93, 2015.
Article in English | MEDLINE | ID: mdl-26049698

ABSTRACT

The development of novel molecular cancer imaging agents has considerably advanced in recent years. Numerous cancer imaging agents have demonstrated remarkable potential for aiding the diagnosis, staging, and treatment planning at the preclinical stage, which in turn has led to a number of agents being approved for human trials. Pancreatic ductal adenocarcinoma is currently the most deadly common carcinoma with an overall 5-year survival rate of about 6%. As detection technologies progress, the need for molecular imaging tools that will allow the diagnosis at an early stage will be crucial to improving patient outcomes. In this review, we will highlight agents that illuminate various cell populations that comprise the tumor: epithelial, endothelial, and stromal tumor cells.


Subject(s)
Epithelial Cells/diagnostic imaging , Molecular Imaging , Pancreatic Neoplasms/diagnostic imaging , Positron-Emission Tomography , Biomarkers, Tumor/blood , Early Detection of Cancer , Endothelial Cells/diagnostic imaging , Endothelial Cells/pathology , Epithelial Cells/pathology , Humans , Neoplastic Cells, Circulating/pathology , Pancreatic Neoplasms/blood , Pancreatic Neoplasms/pathology , Radiography , Stromal Cells/diagnostic imaging , Stromal Cells/pathology
9.
J Nucl Med ; 54(8): 1442-9, 2013 Aug.
Article in English | MEDLINE | ID: mdl-23719858

ABSTRACT

UNLABELLED: Vascular cell adhesion molecule 1 (VCAM-1) plays a major role in the chronic inflammatory processes involved in vulnerable atherosclerotic plaque development. We previously showed that the (99m)Tc-labeled major histocompatibility complex 1-derived peptide B2702p bound specifically to VCAM-1 and allowed the ex vivo imaging of atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits. However, B2702p target-to-background ratio was suboptimal for the in vivo imaging of VCAM-1 expression in atherosclerotic lesions. To improve the target-to-background ratio, 20 derivatives of B2702p (B2702p1-B2702p20) were synthesized using the alanine scan methodology. We hypothesized that (99m)Tc-radiolabeled B2702p derivatives might allow the molecular imaging of VCAM-1 expression in an experimental model of atherosclerosis. METHODS: A mouse model of focal atherosclerotic plaque development induced by left carotid artery ligation in apolipoprotein E double-knockout (ApoE(-/-)) mice was used (n = 82). (99m)Tc-B2702p and (99m)Tc-B2702p1-(99m)Tc-B2702p20 were injected intravenously in anesthetized animals 3 wk after the ligation. Whole-body planar imaging was performed for 3 h. SPECT imaging of 6 additional ligated ApoE(-/-) mice was also performed with (99m)Tc-B2702p1. The animals were then euthanized, and the biodistribution of (99m)Tc-labeled peptides was evaluated by γ-well counting of excised organs. Expression of VCAM-1 in the ligated and contralateral carotid arteries was evaluated by immunohistology. RESULTS: Robust VCAM-1 immunostaining was observed in the left carotid atherosclerotic lesions as a consequence of artery ligation, whereas no VCAM-1 expression was detected in the contralateral carotid artery. Among all evaluated peptides, (99m)Tc-B2702p1 exhibited the most favorable properties. By γ-well counting, there was a significant 2.0-fold increase in the (99m)Tc-B2702p1 left-to-right carotid artery activity ratio (2.6 ± 0.6) and a 3.4-fold increase in the left carotid-to-blood activity ratio (1.4 ± 0.4) in comparison to (99m)Tc-B2702p (1.3 ± 0.2 and 0.4 ± 0.1, respectively, P < 0.05 for both comparisons). Similarly, planar image quantification indicated a higher left-to-right carotid activity ratio in (99m)Tc-B2702p1- than in (99m)Tc-B2702p-injected mice (1.2 ± 0.1 vs. 1.0 ± 0.0, respectively, P < 0.05). Finally, a significantly higher (99m)Tc-B2702p1 activity in the left than in the right carotid artery was observed by SPECT imaging (2.2 ± 0.4 vs. 1.4 ± 0.3 cpm/mm(2)/injected dose, respectively, P < 0.05). CONCLUSION: (99m)Tc-B2702p1 is a potentially useful radiotracer for the in vivo molecular imaging of VCAM-1 expression in atherosclerotic plaques.


Subject(s)
Apolipoproteins E/deficiency , Molecular Imaging/methods , Peptide Fragments , Plaque, Atherosclerotic/diagnosis , Plaque, Atherosclerotic/metabolism , Technetium , Vascular Cell Adhesion Molecule-1/metabolism , Amino Acid Sequence , Animals , Female , Kinetics , Mice , Peptide Fragments/chemistry , Peptide Fragments/pharmacokinetics , Plaque, Atherosclerotic/diagnostic imaging , Tomography, Emission-Computed, Single-Photon , Vascular Cell Adhesion Molecule-1/chemistry
10.
J Nucl Cardiol ; 17(3): 435-43, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20087797

ABSTRACT

BACKGROUND: Myocardial angiogenesis following reperfusion of an infarcted area may impact on patient prognosis and pro-angiogenic treatments are currently evaluated. The non-invasive imaging of angiogenesis would therefore be of potential clinical relevance in these settings. (99m)Tc-RAFT-RGD is a novel (99m)Tc-labeled tracer that targets the alpha(v)beta(3) integrin. Our objective was to determine whether this tracer was suitable for myocardial angiogenesis imaging. METHODS AND RESULTS: A rat model of reperfused myocardial infarction was employed. Fourteen days following reperfusion, the animals were injected with (99m)Tc-RAFT-RGD or with its negative control (99m)Tc-RAFT-RAD. Fourteen animals were dedicated to autoradiographic imaging, infarct staining, and gamma-well counting of myocardial activity. In vivo dual-isotope pinhole SPECT imaging of (201)Tl and (99m)Tc-RAFT-RGD or (99m)Tc-RAFT-RAD was also performed in 11 additional animals. Neovessels were observed by immunostaining in the infarcted and peri-infarct areas. (99m)Tc-RAFT-RGD infarct-to-normal ratios by gamma-well counting and ex vivo imaging (2.5 +/- 0.6 and 4.9 +/- 0.9, respectively) were significantly higher than those of (99m)Tc-RAFT-RAD (1.7 +/- 0.2 and 2.2 +/- 0.4, respectively, P < .05). The infarcted area was readily visible in vivo by SPECT with (99m)Tc-RAFT-RGD but not with (99m)Tc-RAFT-RAD (infarct-to-normal zone activity ratio, 2.5 +/- 0.6 and 1.7 +/- 0.4, respectively, P < .05). CONCLUSION: (99m)Tc-RAFT-RGD allowed the experimental in vivo molecular imaging of myocardial angiogenesis.


Subject(s)
Integrin alphaVbeta3/metabolism , Myocardial Reperfusion Injury/diagnostic imaging , Neovascularization, Physiologic , Organotechnetium Compounds , Peptides, Cyclic , Radiopharmaceuticals , Animals , Autoradiography , Cells, Cultured , Immunohistochemistry , Iodine Radioisotopes , Male , Myocardial Reperfusion Injury/metabolism , Myocardial Reperfusion Injury/physiopathology , Radionuclide Imaging , Rats , Rats, Wistar , Tissue Distribution
11.
Cell Transplant ; 18(12): 1369-79, 2009.
Article in English | MEDLINE | ID: mdl-19849895

ABSTRACT

Human mesenchymal stem cells (hMSC) are a promising source for cell therapy after stroke. To deliver these cells, an IV injection appears safer than a local graft. We aimed to assess the whole-body biodistribution of IV-injected (99m)Tc-HMPAO-labeled hMSC in normal rats (n = 9) and following a right middle cerebral artery occlusion (MCAo, n = 9). Whole-body nuclear imaging, isolated organ counting (at 2 and 20 h after injection) and histology were performed. A higher activity was observed in the right damaged hemisphere of the MCAo group [6.5 +/- 0.9 x 10(-3) % of injected dose (ID)/g] than in the control group (3.6 +/- 1.2 x 10(-3) %ID/g), 20 h after injection. In MCAo rats, right hemisphere activity was higher than that observed in the contralateral hemisphere at 2 h after injection (11.6 +/- 2.8 vs. 9.8 +/- 1.7 x 10(-3) %ID/g). Following an initial hMSC lung accumulation, there was a decrease in pulmonary activity from 2 to 20 h after injection in both groups. The spleen was the only organ in which activity increased between 2 and 20 h. The presence of hMSC was documented in the spleen, liver, lung, and brain following histology. IV-injected hMSC are transiently trapped in the lungs, can be sequestered in the spleen, and are predominantly eliminated by kidneys. After 20 h, more hMSC are found in the ischemic lesion than into the undamaged cerebral tissue. IV delivery of hMSC could be the initial route for a clinical trial of tolerance.


Subject(s)
Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/cytology , Radiopharmaceuticals/administration & dosage , Stroke/therapy , Technetium Tc 99m Exametazime/administration & dosage , Animals , Humans , Injections, Intravenous , Magnetic Resonance Imaging , Rats , Rats, Sprague-Dawley , Stroke/pathology , Tissue Distribution , Whole-Body Counting
12.
J Nucl Cardiol ; 13(1): 75-82, 2006.
Article in English | MEDLINE | ID: mdl-16464720

ABSTRACT

BACKGROUND: Previous studies demonstrated that the intrinsic myocardial washout of bis(N-ethoxy,N-ethyldithiocarbamato)nitrido technetium(V) (technetium 99m N-NOET) was affected by changes occurring in the intravascular compartment such as variations in circulating lipid levels. We sought to determine whether the myocardial kinetics of Tc-99m N-NOET were affected by hyperlipidemia in a clinically relevant experimental model. METHODS AND RESULTS: Tc-99m N-NOET (50 MBq/kg) and thallium 201 (12 MBq/kg) were injected intravenously into hyperlipidemic fa/fa Zucker rats (n=6) and their lean, normolipidemic littermates (n=8), and dual-isotope in vivo planar imaging was performed for 60 minutes. In vivo image quantification indicated significantly faster cardiac washout of Tc-99m N-NOET in fa/fa animals versus lean animals (time constant, 411+/-64 minutes vs 1094+/-226 minutes, respectively; P<.05), whereas Tl-201 cardiac washout was not affected (356+/-85 minutes vs 337+/-53 minutes, respectively; P=not significant). CONCLUSION: The cardiac kinetics of Tc-99m N-NOET, but not those of Tl-201, were accelerated after intravenous injection of the tracer in fa/fa Zucker rats with circulating lipid levels similar to those encountered clinically in hyperlipidemic patients. The relationship between lipidemia and the rate of Tc-99m N-NOET myocardial washout warrants further clinical investigation.


Subject(s)
Hyperlipidemias/diagnostic imaging , Hyperlipidemias/metabolism , Myocardium/metabolism , Obesity/diagnostic imaging , Obesity/metabolism , Organotechnetium Compounds/pharmacokinetics , Thiocarbamates/pharmacokinetics , Animals , Heart/diagnostic imaging , Hyperlipidemias/complications , Kinetics , Metabolic Clearance Rate , Obesity/complications , Organ Specificity , Radionuclide Imaging , Radiopharmaceuticals/pharmacokinetics , Rats , Rats, Zucker , Thinness/complications , Thinness/diagnostic imaging , Thinness/metabolism , Tissue Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...